These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cardiovascular morbidity associated with obstructive sleep apnea syndrome]. Destors M; Tamisier R; Baguet JP; Levy P; Pepin JL Rev Mal Respir; 2014 Apr; 31(4):375-85. PubMed ID: 24750957 [TBL] [Abstract][Full Text] [Related]
3. Vascular responses to hypoxia are not impaired in obstructive sleep apnoea patients free of overt cardiovascular disease. Beaudin AE; Hanly PJ; Raneri JK; Sajobi TT; Anderson TJ; Poulin MJ Exp Physiol; 2019 Apr; 104(4):580-600. PubMed ID: 30697840 [TBL] [Abstract][Full Text] [Related]
4. An update on cardiovascular effects of obstructive sleep apnoea syndrome. Uyar M; Davutoglu V Postgrad Med J; 2016 Sep; 92(1091):540-4. PubMed ID: 27317753 [TBL] [Abstract][Full Text] [Related]
5. Obstructive sleep apnoea and cardiovascular complications: perception versus knowledge. Thomas JJ; Ren J Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):995-1003. PubMed ID: 23082844 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Garvey JF; Taylor CT; McNicholas WT Eur Respir J; 2009 May; 33(5):1195-205. PubMed ID: 19407053 [TBL] [Abstract][Full Text] [Related]
7. Sleep apnoea and the heart. Lévy P; Ryan S; Oldenburg O; Parati G Eur Respir Rev; 2013 Sep; 22(129):333-52. PubMed ID: 23997061 [TBL] [Abstract][Full Text] [Related]
8. Intermittent hypoxia in obese Zucker rats: cardiometabolic and inflammatory effects. Briançon-Marjollet A; Monneret D; Henri M; Joyeux-Faure M; Totoson P; Cachot S; Faure P; Godin-Ribuot D Exp Physiol; 2016 Nov; 101(11):1432-1442. PubMed ID: 27615447 [TBL] [Abstract][Full Text] [Related]
9. Effects of losartan and allopurinol on cardiorespiratory regulation in obstructive sleep apnoea. Morgan BJ; Teodorescu M; Pegelow DF; Jackson ER; Schneider DL; Plante DT; Gapinski JP; Hetzel SJ; Dopp JM Exp Physiol; 2018 Jul; 103(7):941-955. PubMed ID: 29750475 [TBL] [Abstract][Full Text] [Related]
10. Targeting the ROS-HIF-1-endothelin axis as a therapeutic approach for the treatment of obstructive sleep apnea-related cardiovascular complications. Belaidi E; Morand J; Gras E; Pépin JL; Godin-Ribuot D Pharmacol Ther; 2016 Dec; 168():1-11. PubMed ID: 27492897 [TBL] [Abstract][Full Text] [Related]
13. Obstructive sleep apnea: the new cardiovascular disease. Part I: Obstructive sleep apnea and the pathogenesis of vascular disease. Khayat R; Patt B; Hayes D Heart Fail Rev; 2009 Sep; 14(3):143-53. PubMed ID: 18807180 [TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of cardiovascular damage in obstructive sleep apnea]. Torre-Bouscoulet L; Castorena-Maldonado A; Sada-Ovalle I; Meza-Vargas MS Rev Invest Clin; 2008; 60(6):502-16. PubMed ID: 19378837 [TBL] [Abstract][Full Text] [Related]
15. Carotid body potentiation induced by intermittent hypoxia: implications for cardiorespiratory changes induced by sleep apnoea. Iturriaga R; Moya EA; Del Rio R Clin Exp Pharmacol Physiol; 2009 Dec; 36(12):1197-204. PubMed ID: 19473190 [TBL] [Abstract][Full Text] [Related]